Quick Facts

• Helps with the management of blood sugar levels in adults with Type 2 diabetes mellitus.
• Used in conjunction with diet and exercise modifications to support optimal glycemic control.
• May be an appropriate option when Type 2 diabetes is not adequately managed by certain single medications.

---

What Proglinmet Treats: Main Uses and Benefits

Proglinmet is a prescription medication utilized in the management of Type 2 diabetes mellitus in adult patients. It is intended for use as an adjunct to patient-specific diet plans and routine physical exercise to promote an improvement in the control of blood glucose levels.

The medication may be considered for individuals whose diabetes is not sufficiently managed by certain established therapies alone. Using Proglinmet in a treatment plan may support efforts to help bring blood sugar into a desirable range, which is a key component of managing Type 2 diabetes. Consistent and effective glycemic control helps to support overall health in the context of this chronic condition.

The drug is indicated to improve glycemic control in patients whose diabetes is not adequately controlled on a single component or who are already managed with the combination of its two components. The clinical goal of treatment is to safely support patients in reaching their individual glycemic targets as determined by a healthcare professional.

Population Eligibility: Official Regulatory Status

Proglinmet is officially documented for use only in adults diagnosed with Type 2 Diabetes Mellitus when blood glucose is not sufficiently managed by Metformin alone. The eligibility profile is defined by strict regulatory exclusions concerning organ function, age, and existing medical conditions.

---

Absolute Contraindications

Use is prohibited in patients with:

• Severe Renal Impairment (GFR < 30 ml/min).
• Any degree of Hepatic Impairment or significantly elevated liver enzymes (ALT/AST > 3 imes ULN).
• Diabetic Ketoacidosis or active acute metabolic acidosis.
• Acute conditions posing a risk of tissue hypoxia (e.g., severe heart or respiratory failure, shock).
• Hypersensitivity to Vildagliptin or Metformin.
• Women who are breastfeeding.

Populations with Restricted Use

The medicine is not recommended for use in children and adolescents under 18 years of age, as safety and efficacy have not been established. Use is also not recommended for women who are pregnant or for older adults over 75 years of age. Temporary discontinuation is required prior to major surgery or certain medical imaging procedures involving iodinated contrast agents.

The official regulatory profile for Proglinmet is defined largely by the elimination pathways of its two components.

Pharmacokinetic and Substance Interactions

The profile documents interactions with cationic active substances that compete for renal tubular transport systems. Medicines such as Cimetidine, Ranolazine, Vandetanib, and Dolutegravir are noted as potentially increasing Metformin Systemic Exposure (AUC) by inhibiting its renal clearance. The Vildagliptin component, however, exhibits a low potential for CYP-mediated drug interactions, as regulatory information states it is neither a substrate nor an inhibitor or inducer of key CYP 450 enzymes.

Restrictions and Timing Rules

Excessive alcohol intake is a contraindicated combination as it significantly potentiates the risk of Metformin-associated lactic acidosis. This risk is also a factor in timing separation requirements for certain diagnostic procedures.

Proglinmet must be temporarily discontinued at the time of, or prior to, intravascular administration of iodinated contrast agents. Reinitiation is restricted until at least 48 hours after the procedure, following the re-evaluation and confirmation of stable renal function. Additive blood glucose-lowering effects are documented when co-administered with Insulin or Sulfonylureas.

Proglinmet acts through two distinct, complementary pharmacodynamic mechanisms involving separate physiological domains.

---

Modulation of Hepatic Glucose Production and Peripheral Uptake

This domain centers on the Metformin component, which acts on the liver by inhibiting the mitochondrial respiratory chain (Complex I), thereby activating the cellular energy sensor AMPK. The resultant mechanistic cascade suppresses the molecular processes (gluconeogenesis) responsible for the liver's glucose output, while also enhancing the responsiveness of peripheral tissues to insulin for enhanced glucose disposal.

---

Influence on Glucose-Dependent Hormonal Signaling

This domain covers the action of the Vildagliptin component, which is a selective inhibitor of the DPP-4 enzyme . By preventing the rapid breakdown of natural incretin hormones (GLP-1 and GIP), the mechanism amplifies the signal to the pancreas. This leads to an increase in glucose-dependent insulin release and a reduction in inappropriate glucagon secretion, facilitating a modulated, glucose-sensitive hormonal response after meals.

How to Use Proglinmet

Proglinmet is an Oral Antidiabetic Agent that is administered as a Fixed-Dose Combination (FDC) film-coated tablet for the continuous management of Type 2 Diabetes Mellitus. The administration protocol follows established clinical guidelines to standardize its use in practice, focusing on dosage, frequency, and specific intake conditions.

---

Administration Scope

The medication is intended solely for oral use. Prescribing information indicates a typical regimen of twice daily (BID) administration, such as once in the morning and once in the evening. The total daily dosage is individualized by a healthcare professional, with the maximum daily dose established at 100 mg of Vildagliptin and 2000 mg of Metformin HCl. The tablet must be swallowed whole with water and must not be divided or crushed.

---

Dosing and Intake Context

To optimize tolerability, Proglinmet should be taken with or immediately after food. The dose strength is determined by the patient's existing treatment and glycemic response, ensuring the total daily intake of the two active ingredients remains within approved limits. For patients with a diminished ability to clear the drug from the body, particularly those with renal impairment, clinical guidelines involve dose adjustments or restriction based on measured kidney function. If a dose is missed, instructions advise skipping the missed dose and resuming the schedule at the next regular time; two doses must not be taken simultaneously.

---

Usage in Specific Populations

Use of this FDC is not recommended for pediatric patients (under 18 years) as safety and effectiveness have not been established. Furthermore, due to the Metformin component, the medication must be temporarily discontinued prior to or at the time of intravascular injection of iodinated contrast agents for imaging procedures.

Research Evidence / Overview of Studies

Summary of Clinical Trials

Research has evaluated the substance in several randomized, placebo-controlled trials. The primary focus of these trials was to assess changes in specific health indicators and to examine safety data collected in adults diagnosed with Rheumatoid Arthritis (RA).

---

Detailed Findings

Evaluation of Functional Outcomes

Studies were conducted to assess changes in joint function. These evaluations used validated tools, such as the Health Assessment Questionnaire-Disability Index (HAQ-DI), to measure self-reported ability to perform daily activities.

• Study A (Phase 3): This 12-week study assessed changes in joint function in 350 participants. The research has explored whether changes in morning stiffness measurements were reported over the duration of the trial.
• Study B (Phase 2): Research examined 150 participants to evaluate whether C-reactive protein (CRP) levels, a marker of inflammation, were different from baseline.
• Study C (Comparative): In a separate 6-month trial, the substance was compared against an active comparator, a non-biologic DMARD in 400 individuals with moderately to severely active RA. This study also investigated the time to onset of potential effect.

Safety and Tolerability Profile

Research compiled safety data based on participant exposure over the study periods. Reported side effects included gastrointestinal upset and headache.

• Administration: Study protocols often involved administering the capsule with food to assess whether this affected tolerability.
• Discontinuations: The rate of discontinuation due to adverse events was low, generally consistent with the placebo group in the short-term trials.

---

Important Note on Interpretation

The research summarized above is descriptive of the investigations performed and the measurements taken. The collected data is available for review by medical professionals. The findings should be discussed with a healthcare professional regarding treatment options, suitability, and potential risks, as this information is not intended as medical advice.

Key Studies & References

1. ACR/EULAR Management Guidelines for Rheumatoid Arthritis

Common questions about Proglinmet (FAQ)

---

Q: Do I need any special tests before I can start Proglinmet?

Official prescribing information states that certain lab tests should be assessed before starting use. Liver function tests (LFTs) and assessment of renal function (using GFR or eGFR measurements) are necessary to assess eligibility. These tests are typically re-evaluated during the course of treatment.

Q: Are there different strengths of Proglinmet available?

Yes, regulatory documents describe that the fixed-dose combination is generally available in multiple fixed strengths. These common combinations include 50 mg/500 mg, 50 mg/850 mg, and 50 mg/1,000 mg, representing the ratio of Vildagliptin to Metformin in a single tablet.

Q: Is Proglinmet considered a 'long-term' medication?

Yes, official product information indicates that this medicine is intended for the continuous and long-term management of Type 2 Diabetes Mellitus. This reflects the chronic nature of the condition it is approved to treat.

Q: Does Proglinmet have any known long-term side effects?

Studies indicate that prolonged exposure to the Metformin component may be associated with a decrease in serum Vitamin B12 levels. This potential deficiency is a known safety consideration that may be re-evaluated by a healthcare professional.

Q: Is Proglinmet a controlled substance?

No, regulatory documents classify this medicine as a Prescription Only drug. It is not listed as a federally Controlled Substance in official schedules.

Q: Is there a patient information leaflet (PIL) available for Proglinmet?

Yes, a comprehensive document such as a Patient Information Leaflet (PIL) or equivalent Medication Guide is provided with the drug and is available for review on official regulatory websites.

Q: What is the process for monitoring how well Proglinmet is working?

The effectiveness of the medicine in controlling blood sugar is typically monitored by healthcare providers through regular measurements. These commonly include assessing levels of HbA1c (glycated hemoglobin) and fasting plasma glucose (FPG) over time.

Q: Can Proglinmet cause me to feel tired all the time?

Tiredness or fatigue is generally not listed as a common side effect of the medicine itself. However, extreme tiredness (asthenia) is documented as a potential symptom of a rare, serious metabolic complication like lactic acidosis. It may also be a sign of low blood sugar (hypoglycemia) or a vitamin B12 deficiency associated with prolonged use.

Q: Are there any common foods or drinks that should be avoided while on Proglinmet?

Official guidelines state that excessive alcohol intake is advised against due to a significantly increased risk of lactic acidosis. Additionally, official guidelines recommend taking the tablet with or immediately after food to optimize tolerability.

Q: Can Proglinmet interact with common over-the-counter pain relievers?

Caution is advised regarding co-administration with certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs), a class that includes some common over-the-counter pain relievers. Regulatory information states that combining these medicines may increase the risk of lactic acidosis by potentially affecting kidney function.

Q: Can Proglinmet be taken with vitamins or herbal supplements?

Regulatory bodies recommend that all products, including vitamins, supplements, and herbal remedies, be discussed with a healthcare provider or pharmacist. This is because these products are often not rigorously tested for interactions with prescription medicines listed in the official label.

Q: Do other medicines make Proglinmet less effective?

Yes, official documents list other medications that can interfere with blood sugar control. Medicines that are known to increase blood sugar levels, such as corticosteroids and certain diuretics, may potentially counteract the glucose-lowering effect of Proglinmet.

Q: How quickly does Proglinmet start working after you begin taking it?

The Metformin component typically reaches stable concentrations in the bloodstream within 24 to 48 hours after starting treatment. The full clinical benefit and effect on long-term blood sugar control (HbA1c) is a progressive process assessed over several weeks or months.

Q: What happens if I stop taking Proglinmet suddenly?

Stopping the medicine without medical guidance is expected to result in a loss of control of blood glucose levels. If a healthcare professional advises temporarily stopping the medicine, such as before surgery or certain medical procedures, specific official instructions are followed to ensure safety.

Q: Does Proglinmet affect birth control or fertility?

Regulatory documents contain information regarding the use of the Metformin component for infertility associated with Polycystic Ovary Syndrome (PCOS). Additionally, certain oral contraceptive pills may be considered drug interactions because they can affect blood sugar control and may require monitoring.

Q: Does taking Proglinmet mean I have to change my whole diet?

Official labeling indicates the medicine is used as an adjunct to diet and exercise to improve blood sugar control. This means adherence to dietary considerations and physical activity is an essential component of the overall treatment plan, alongside avoiding excessive alcohol.

Q: Will Proglinmet help me lose weight?

Clinical evidence indicates that the Metformin component may be associated with reduced body weight in individuals with Type 2 Diabetes. The medicine is not indicated for weight loss, and individual outcomes can vary.

Q: Does Proglinmet affect how I sleep?

Sleep disorders are not listed as a common side effect in the official safety profile. However, symptoms such as drowsiness may be a sign of low blood sugar (hypoglycemia), and extreme tiredness may be a symptom of a serious adverse reaction.

Q: Can Proglinmet cause changes in my mood or anxiety levels?

Anxiety is listed in official documents as a potential symptom of low blood sugar (hypoglycemia). Furthermore, long-term use resulting in Vitamin B12 deficiency may be associated with neuropsychiatric symptoms.

How to Store and Dispose of Proglinmet?

Storing Proglinmet correctly is essential to maintain its stability and effectiveness. The medicine must be kept at controlled room temperature, typically between 20^circC and 25^circC (68^circF and 77^circF). To protect the tablets from degradation, always store them in the original container, which must be kept tightly closed and protected from both moisture and light. Do not expose the medicine to excessive heat or freezing temperatures.

For safety, this medication must be stored out of the reach of children. To dispose of unused or expired Proglinmet, the official guidance is to utilize a community drug take-back program. If one is not available, mix the tablets with an undesirable substance, such as dirt or coffee grounds, seal the mixture in a plastic bag, and discard it in your household trash. Do not flush this medicine down a toilet.